HS LifeSciences was established in 2008 by seasoned biotech entrepreneurs with many years of experience in managing biotech companies. The lessons learned over the years have been distilled into a new business model centered on the foundation and growth of new life sciences companies without the need for conventional multiple rounds of equity-based financing.

 

HS LifeSciences supports new life science companies during their foundation and early growth phases by complementing the scientific founders’ R&D vision with management, financial and commercial experience.

 

In addition, we have established a highly entrepreneurial approach to financing through an investment fund - QureInvest II, which we manage on behalf of the General Partner. QureInvest II has ca. €70MM under management and is focused on investing in novel research and development innovation in the life sciences sector.

 

Patient benefit remains the utmost priority for our portfolio companies and our overriding goal is to bring novel therapies to the market in the fastest possible manner. Our business model enables our portfolio companies to pursue their role as innovation powerhouses bringing together their medical innovation with the biopharmaceutical industry in structures that are tailored to the needs of both the biopharmaceutical partner and our portfolio companies.